Dendreon Corp (DNDN): Today's Featured Drugs Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Dendreon ( DNDN) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.4%. By the end of trading, Dendreon rose 8 cents (1.3%) to $6.33 on light volume. Throughout the day, 4.3 million shares of Dendreon exchanged hands as compared to its average daily volume of 6.2 million shares. The stock ranged in a price between $6.25-$6.45 after having opened the day at $6.31 as compared to the previous trading day's close of $6.25. Other companies within the Drugs industry that increased today were: Keryx Biopharmaceuticals ( KERX), up 76.6%, Ventrus Biosciences ( VTUS), up 23.5%, Novogen ( NVGN), up 19.1%, and Bioline Rx ( BLRX), up 11.7%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics to enhance cancer treatment options for patients. Dendreon has a market cap of $972.2 million and is part of the health care sector. Shares are up 16.6% year to date as of the close of trading on Friday. Currently there are two analysts that rate Dendreon a buy, six analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates Dendreon as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, generally disappointing historical performance in the stock itself and generally high debt management risk.

On the negative front, Repros Therapeutics ( RPRX), down 40.3%, Cormedix ( CRMD), down 10.1%, Oxygen Biotherapeutics ( OXBT), down 6.4%, and Tianyin Pharmaceutical ( TPI), down 5.7%, were all laggards within the drugs industry with Herbalife ( HLF) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.
null

If you liked this article you might like

Biotech-Twitter 2014: A Look Back at the Biotech Year Through the Twitter Lens

Where Are They Now? A Look Back at the Best & Worst Biotech CEOs

Nominees for Absolute Worst Biotechnology CEOs of 2014 Are ...

Using Re-Engineered Immune Cells to Kill Leukemia Induces Lasting Remissions

Stock Market Today: S&P 500 Eyes Strong Finish for 2014; Alibaba Spikes